A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Clinical Cancer Research|2019Cited by 90
What predicts patient non-attendance at urgent referral appointments for suspected cancer?Rebecca Sheridan, Peter M. Knapp, P Melling et al.|European Journal of Surgical Oncology|2017Cited by 1
Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Unknown|2023Cited by 1
Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Unknown|2023Cited by 1